Benzisothiazolone Derivatives Exhibit Cytotoxicity in Hodgkin’s Lymphoma Cells through NF-κB Inhibition and are Synergistic with Doxorubicin and Etoposide

Author(s): Natarajan Nandakumar, Pushparathinam Gopinath, Jacob Gopas*, Kannoth M. Muraleedharan*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 20 , Issue 6 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The authors investigated the NF-κB inhibitory role of three Benzisothiazolone (BIT) derivatives (1, 2 and 3) in Hodgkin’s Lymphoma cells (L428) which constitutively express activated NF-κB. All three compounds showed dose-dependent NF-κB inhibition (78.3, 70.7 and 34.6%) in the luciferase reporter gene assay and were found cytotoxic at IC50 values of 3.3μg/ml, 4.35μg/ml and 13.8μg/ml, respectively by the XTT assay. BIT 1and BIT 2 (but not BIT 3) suppressed both NF-κB subunits p50 and p65 in cytoplasmic and nuclear extracts in a concentration-dependent manner. Furthermore, BIT 1 showed a moderate synergistic effect with the standard chemotherapy drugs etoposide and doxorubicin, whereas BIT 2 and 3 showed a moderate additive effect to antagonistic effect. Cisplatin exhibited an antagonist effect on all the compounds tested under various concentrations, except in the case of 1.56μg/ml of BIT 3 with 0.156μg/ml of cisplatin. The compounds also inhibited the migration of adherent human lung adenocarcinoma cells (A549) in vitro. We conclude that especially BIT 1 and BIT 2 have in vitro anti-inflammatory and anti-cancer activities, which can be further investigated for future potential therapeutic use.

Methods: Inspired by the electrophilic sulfur in Nuphar alkaloids, monomeric and dimeric benzisothiazolones were synthesized from dithiodibenzoic acid and their NF-κB inhibitory role was explored. NF-κB inhibition and cytotoxicity of the synthesized derivatives were studied using luciferase reporter gene assay and XTTassay. Immunocytochemistry studies were performed using L428 cells. Cell migration assay was conducted using the A549 cell line. L428 cells were used to conduct combination studies and the results were plotted using CompuSyn software.

Results: Benzisothiazolone derivatives exhibited cytotoxicity in Hodgkin’s Lymphoma cells through NF-κB inhibition. Potent compounds showed suppression of both NF-κB subunits p50 and p65 in a concentrationdependent manner, both in cytoplasmic and nuclear extracts. Combination studies suggest that benzisothiazolone derivatives possess a synergistic effect with etoposide and doxorubicin. Furthermore, the compounds also inhibited the migration of A549 cells.

Conclusion: Benzisothiazolones bearing one or two electrophilic sulfur atoms as part of the heterocyclic framework exhibited cytotoxicity in Hodgkin’s Lymphoma cells through NF-κB inhibition. In addition, these derivatives also exhibited a synergistic effect with etoposide and doxorubicin along with the ability to inhibit the migration of A549 cells. Our study suggests that BIT-based new chemical entities could lead to potential anticancer agents.

Keywords: Benzisothiazolones, NF-κB, combination studies, anticancer, Hodgkin's lymphoma, etoposide.

[1]
Jost, P.J.; Ruland, J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood, 2007, 109(7), 2700-2707.
[http://dx.doi.org/10.1182/blood-2006-07-025809] [PMID: 17119127]
[2]
Küppers, R.; Engert, A.; Hansmann, M-L. Hodgkin lymphoma. J. Clin. Invest., 2012, 122(10), 3439-3447.
[http://dx.doi.org/10.1172/JCI61245] [PMID: 23023715]
[3]
Brasier, A.R. The NF-kappaB regulatory network. Cardiovasc. Toxicol., 2006, 6(2), 111-130.
[http://dx.doi.org/10.1385/CT:6:2:111] [PMID: 17303919]
[4]
Baeuerle, P.A.; Henkel, T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol., 1994, 12, 141-179.
[http://dx.doi.org/10.1146/annurev.iy.12.040194.001041] [PMID: 8011280]
[5]
Karin, M.; Lin, A. NF-kappaB at the crossroads of life and death. Nat. Immunol., 2002, 3(3), 221-227.
[http://dx.doi.org/10.1038/ni0302-221] [PMID: 11875461]
[6]
Gilmore, T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene, 2006, 25(51), 6680-6684.
[http://dx.doi.org/10.1038/sj.onc.1209954] [PMID: 17072321]
[7]
Gupta, S.C.; Sundaram, C.; Reuter, S.; Aggarwal, B.B. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta BBA - Gene Regul. Mech., , 2010, 1799, 775-787.
[8]
Nandakumar, N.; Muthuraman, S.; Gopinath, P.; Nithya, P.; Gopas, J.; Kumar, R.S. Synthesis of coumaperine derivatives: Their NF-κB inhibitory effect, inhibition of cell migration and their cytotoxic activity. Eur. J. Med. Chem., 2017, 125, 1076-1087.
[http://dx.doi.org/10.1016/j.ejmech.2016.10.047] [PMID: 27810594]
[9]
Ozer, J.; Eisner, N.; Ostrozhenkova, E.; Bacher, A.; Eisenreich, W.; Benharroch, D.; Golan-Goldhirsh, A.; Gopas, J. Nuphar lutea thioalkaloids inhibit the nuclear factor kappaB pathway, potentiate apoptosis and are synergistic with cisplatin and etoposide. Cancer Biol. Ther., 2009, 8(19), 1860-1868.
[http://dx.doi.org/10.4161/cbt.8.19.9567] [PMID: 19713755]
[10]
Siegemund, A.; Taubert, K.; Schulze, B. 1,2-Benzisothiazol-3(2H)-ones, part II: Synthesis, reactions, and biological activity. Sulfur Rep., 2002, 23, 279-319.
[http://dx.doi.org/10.1080/0196177021000011176]
[11]
Gopinath, P.; Ramalingam, K.; Muraleedharan, K.M.; Karunagaran, D. Benzisothiazolones arrest the cell cycle at the G2/M phase and induce apoptosis in Hela cells. MedChemComm, 2013, 4, 749-752.
[http://dx.doi.org/10.1039/c3md00034f]
[12]
Tada, N.; Jansen, D.J.; Mower, M.P.; Blewett, M.M.; Umotoy, J.C.; Cravatt, B.F.; Wolan, D.W.; Shenvi, R.A. Synthesis and sulfur electrophilicity of the nuphar thiaspirane pharmacophore. ACS Cent. Sci., 2016, 2(6), 401-408.
[http://dx.doi.org/10.1021/acscentsci.6b00113] [PMID: 27413784]
[13]
Ranganathan, S.; Muraleedharan, K.M.; Bharadwaj, P.; Chatterji, D.; Karle, I. The design and synthesis of redox core-alpha amino acid composites based on thiol-disulfide exchange mechanism and a comparative study of their zinc abstraction potential from (CCXX) boxes in protein. Tetrahedron, 2002, 58(14), 2861-2874.
[http://dx.doi.org/10.1016/S0040-4020(02)00159-X]
[14]
Dekker, F.J.; Ghizzoni, M.; van der Meer, N.; Wisastra, R.; Haisma, H.J. Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. Bioorg. Med. Chem., 2009, 17(2), 460-466.
[http://dx.doi.org/10.1016/j.bmc.2008.12.008] [PMID: 19111471]
[15]
Hayakawa, N.; Nozawa, K.; Ogawa, A.; Kato, N.; Yoshida, K.; Akamatsu, Ki.; Tsuchiya, M.; Nagasaka, A.; Yoshida, S. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry, 1999, 38(35), 11501-11507.
[http://dx.doi.org/10.1021/bi982829k] [PMID: 10471302]
[16]
Dahl, R.; Bravo, Y.; Sharma, V.; Ichikawa, M.; Dhanya, R-P.; Hedrick, M.; Brown, B.; Rascon, J.; Vicchiarelli, M.; Mangravita-Novo, A.; Yang, L.; Stonich, D.; Su, Y.; Smith, L.H.; Sergienko, E.; Freeze, H.H.; Cosford, N.D. Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J. Med. Chem., 2011, 54(10), 3661-3668.
[http://dx.doi.org/10.1021/jm101401a] [PMID: 21539312]
[17]
Tiew, K-C.; Dou, D.; Teramoto, T.; Lai, H.; Alliston, K.R.; Lushington, G.H.; Padmanabhan, R.; Groutas, W.C. Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives. Bioorg. Med. Chem., 2012, 20(3), 1213-1221.
[http://dx.doi.org/10.1016/j.bmc.2011.12.047] [PMID: 22249124]
[18]
Dou, D.; Alex, D.; Du, B.; Tiew, K-C.; Aravapalli, S.; Mandadapu, S.R.; Calderone, R.; Groutas, W.C. Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives. Bioorg. Med. Chem., 2011, 19(19), 5782-5787.
[http://dx.doi.org/10.1016/j.bmc.2011.08.029] [PMID: 21903403]
[19]
Alex, D.; Gay-Andrieu, F.; May, J.; Thampi, L.; Dou, D.; Mooney, A.; Groutas, W.; Calderone, R. Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets. Antimicrob. Agents Chemother., 2012, 56(9), 4630-4639.
[http://dx.doi.org/10.1128/AAC.00477-12] [PMID: 22687516]
[20]
Gopinath, P.; Yadav, R.K.; Shukla, P.K.; Srivastava, K.; Puri, S.K.; Muraleedharan, K.M. Broad spectrum anti-infective properties of benzisothiazolones and the parallels in their anti-bacterial and anti-fungal effects. Bioorg. Med. Chem. Lett., 2017, 27(5), 1291-1295.
[http://dx.doi.org/10.1016/j.bmcl.2017.01.027] [PMID: 28159413]
[21]
Jungnickel, B.; Staratschek-Jox, A.; Bräuninger, A.; Spieker, T.; Wolf, J.; Diehl, V.; Hansmann, M-L.; Rajewsky, K.; Küppers, R. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin’s lymphoma. J. Exp. Med., 2000, 191(2), 395-402.
[http://dx.doi.org/10.1084/jem.191.2.395] [PMID: 10637284]
[22]
Emmerich, F.; Theurich, S.; Hummel, M.; Haeffker, A.; Vry, M.S.; Döhner, K.; Bommert, K.; Stein, H.; Dörken, B. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J. Pathol., 2003, 201(3), 413-420.
[http://dx.doi.org/10.1002/path.1454] [PMID: 14595753]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 6
Year: 2020
Published on: 14 June, 2020
Page: [715 - 723]
Pages: 9
DOI: 10.2174/1871520620666200213103513
Price: $65

Article Metrics

PDF: 18
HTML: 2